Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting

European Journal of Clinical Pharmacology

Volumn 66, Issue 4, 2010, Pages 375-381

  Haberl, Annette ^a   Moesch, Manfred ^a   Nisius, Gabriele ^a   Stephan, Christoph ^a   Bickel, Markus ^a   Khaykin, Pavel ^a   Kurowski, Michael ^b   Brodt, Reinhard ^a   Von Hentig, Nils ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Vivantes Auguste Viktoria Klinikum   (Germany)

Author keywords

Atazanavir; HIV; Low dose ritonavir; Methadone maintenance therapy; Pharmacokinetics; Protease inhibitor

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; COTRIMOXAZOLE; DIDANOSINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; METHADONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ATAZANAVIR; OLIGOPEPTIDE; PYRIDINE DERIVATIVE; RITONAVIR;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERBILIRUBINEMIA; HYPERTRICHOSIS; LIBIDO DISORDER; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; OPIATE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; STEADY STATE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; BLOOD; DRUG MONITORING; HUMAN IMMUNODEFICIENCY VIRUS 1; LIQUID CHROMATOGRAPHY; PLASMA; SOLUTION AND SOLUBILITY; VIROLOGY; VIRUS INFECTION;

ADULT; CHROMATOGRAPHY, LIQUID; DRUG MONITORING; FEMALE; HIV-1; HUMANS; MALE; METHADONE; OLIGOPEPTIDES; PHARMACEUTICAL SOLUTIONS; PLASMA; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SOLUTIONS; VIRUS DISEASES;

EID: 77953951458     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0767-8     Document Type: Article

References (19)

1. Bristol Myers Squibb Company (2007) Reyataz product information. NDA 21-567/S-012. Bristol Meyers Squib, Princeton, NJ
2. CBER (1999) Guidance for the industry. In vivo drug metabolism/drug interactions studies. Study design, data analysis and recommendations for dosing and labeling. Center for Biologics Evaluation and Research (CBER), Rockville
3. Burger DM, Muller RJ, van der Leur MR, la Porte CJL (2002) Lopinavir plasma levels are significantly higher in female than in male HIV-1 infected patients. In: Program and abstracts of the 3rd Int Workshop Clinical Pharmacology of HIV Therapy. Washington D.C.
4. DiFrancesco R, Fischl MA, Donnelly J, Zingman BS, McCance-Katz EF, Moody DE, Reichman RC, Gripshover B, Morse GD (2007) Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. J Pharm Biomed Anal 44:188-195
5. Esser S, Staszewski S, Haberl A, Mulcahy F, Gölz J, Lazzarin A, Teofilo E, Vera J, Körber A, Ranneberg B, Gallo L (2008) 3OD- Once-daily (OD) TDF-containing HAART in HIV-1-infected former IVDU-patients receiving opiate substitution: efficacy, tolerability and adherence. In: 9th Int Congress Drug Therapy in HIV Infection. Glasgow
6. Esser S, Staszewski S, Haberl A, Mulcahy F, Gölz J, Lazzarin A, Teofilo E, Vera J, Körber A, Ranneberg B, Gallo L (2008) An open-label multicenter study to assess efficacy, tolerability and adherence of a once-daily (OD) TDF-Containing HAART in HIV-1-Infected Former IVDU-Patients receiving opiate substitution-final 48 weeks analysis of 3OD. In: 17th International AIDS Conference. Mexico City, Mexico
7. Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E (2005) Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. Aids 19:1635-1641
8. Gatti G, De Pascalis CR, De Luca A et al (2002) Predictors of amprenavir parameters of drug exposure in heavily pretreated HIV positive patients (abstract). In: Proc 6th Int Congress in Drug Therapy in HIV Infection. Glasgow, p 165
9. Hsyu PH, Lillibridge J, Daniels E, Kerr BM(2006) Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users. Biopharm Drug Dispos 27:61-68
10. Johnson V, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes D, Pillay D, Schapiro J, Telenti A, Richman D (2005) Update of the drug resistance mutations in HIV-1: 2005. Topics HIV Med 13:125-131
11. Kurowski M, Sternfeld T, Sawyer A, Hill A, Mocklinghoff C (2003) Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med 4:94-100
12. McCance-Katz EF, Moody DE, Morse GD, Ma Q, Difrancesco R, Friedland G, Pade P, Rainey PM (2007) Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 91:269-278
13. Pai MP, Schriever CA, Diaz-Linares M, Novak RM, Rodvold KA (2004) Sex-related differences in the pharmacokinetics of oncedaily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy 24:592-599
14. Stephan C, Hentig N, Kourbeti I, Dauer B, Mosch M, Lutz T, Klauke S, Harder S, Kurowski M, Staszewski S (2004) Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. Aids 18:503-508
15. Tossonian HK, Raffa JD, Grebely J, Trotter B, Viljoen M, Mead A, Khara M, McLean M, Duncan F, Fraser C, DeVlaming S, Conway B (2007) Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy program. J Acquir Immune Defic Syndr 45:324-327
16. Umeh O, Currier J (2006) Sex differences in the pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol 2:273-283
17. von Hentig N (2008) Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today (Barc) 44:103-132
18. von Hentig N, Babacan E, Stephan C, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A (2008) Pharmacokinetics of atazanavir/ritonavir in HIV-1 infected adult outpatients is not affected by gender-related cofactors. J Antimicrob Chemother 62:579-582
19. von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S (2007) Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavirboosted atazanavir in HIV-1-infected adults. Eur J Clin Pharmacol 63:935-940